Cargando…
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoubtedly exp...
Autores principales: | Lemal, Richard, Tournilhac, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676603/ https://www.ncbi.nlm.nih.gov/pubmed/31370892 http://dx.doi.org/10.1186/s40425-019-0686-x |
Ejemplares similares
-
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
por: Mancikova, Veronika, et al.
Publicado: (2021) -
Telomere status in chronic lymphocytic leukemia with TP53 disruption
por: Guièze, Romain, et al.
Publicado: (2016) -
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
por: Todorovic, Zeljko, et al.
Publicado: (2022) -
Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia
por: Heyman, Benjamin M., et al.
Publicado: (2022) -
Docosahexaenoic Acid Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells
por: Guièze, Romain, et al.
Publicado: (2015)